CRBU — Caribou Biosciences Income Statement
0.000.00%
Last trade - 00:00- $81.84m
- -$127.69m
- $9.99m
Annual income statement for Caribou Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 12.4 | 9.6 | 13.9 | 34.5 | 9.99 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 48.5 | 75 | 120 | 151 | 177 |
| Operating Profit | -36.1 | -65.4 | -106 | -116 | -167 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -36.1 | -66.6 | -99.4 | -102 | -149 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -34.3 | -66.9 | -99.4 | -102 | -149 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -34.3 | -66.9 | -99.4 | -102 | -149 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -34.3 | -66.9 | -99.4 | -102 | -149 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.605 | -1.13 | -1.64 | -1.38 | -1.65 |
| Dividends per Share |